Journal of Andrology Cross-Journal Searching
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brennemann, W.
Right arrow Articles by Klingmuller, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brennemann, W.
Right arrow Articles by Klingmuller, D.

Journal of Andrology, Vol 14, Issue 6 407-410, Copyright © 1993 by The American Society of Andrology

JOURNAL ARTICLE

Treatment of idiopathic erectile dysfunction in men with the opiate antagonist naltrexone--a double-blind study

W. Brennemann, B. Stitz, H. Van Ahlen, K. A. Brensing and D. Klingmuller
Department of Clinical Biochemistry, University of Bonn, Germany.

Opiate antagonists can indirectly stimulate the secretion of luteinizing hormone (LH) and testosterone, as well as sexual functions in animals and humans. We therefore treated 20 otherwise healthy men with idiopathic erectile dysfunction aged 46.3 +/- 2.7 years (mean +/- SE, range 23.9-63.3) in a double-blind study with an opiate antagonist, naltrexone, or placebo. The erectile dysfunction of these men had persisted for 3.6 +/- 0.5 years despite libido maintenance; standard procedures had excluded any organic causes. Trial duration was 12 weeks overall. After a 4-week forerun, the patients received at first 25 mg naltrexone/day orally or placebo for 4 weeks followed by 4 weeks of a 50-mg dose of naltrexone/day or placebo. Each day the patients filled out a questionnaire detailing libido, degree of erection, frequency of sexual intercourse, and spontaneous morning erections. Serum concentrations of gonadotropins and testosterone were determined radioimmunologically in the initial stage and at the end of each phase. Both patient collectives had similar initial factors. The group treated with naltrexone showed a significant rise in spontaneous early morning erections during the treatment: from 2.8 +/- 0.3 to 4.2 +/- 0.3 a week (P < 0.001). The placebo group showed no significant change in spontaneous erections (2.4 +/- 0.3 and 2.6 +/- 0.3, respectively). The subjective parameters, however, such as libido, degree of erection, and frequency of sexual intercourse showed no significant difference within each group. There was no difference in LH, follicle-stimulating hormone, or testosterone concentrations in both groups. Thus, treatment with naltrexone significantly raises the rate of spontaneous early morning erections when compared to controls.(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:


Home page
 Endocr. Rev.Home page
F. R. Kandeel, V. K. T. Koussa, and R. S. Swerdloff
Male Sexual Function and Its Disorders: Physiology, Pathophysiology, Clinical Investigation, and Treatment
Endocr. Rev., June 1, 2001; 22(3): 342 - 388.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
C. M. Meston and P. F. Frohlich
The Neurobiology of Sexual Function
Arch Gen Psychiatry, November 1, 2000; 57(11): 1012 - 1030.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by The American Society of Andrology.